1. Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists.
- Author
-
Ami D, Franco AR, Artusa V, Romerio A, Shaik MM, Italia A, Anguita J, Pasco S, Mereghetti P, Peri F, and Natalello A
- Subjects
- Animals, Spectroscopy, Fourier Transform Infrared, Mice, Humans, Drug Design, RAW 264.7 Cells, Toll-Like Receptor 4 agonists, Toll-Like Receptor 4 metabolism, Machine Learning, Lipopolysaccharides pharmacology
- Abstract
In this work, we present the potential of Fourier transform infrared (FTIR) microspectroscopy to compare on whole cells, in an unbiased and untargeted way, the capacity of bacterial lipopolysaccharide (LPS) and two rationally designed molecules (FP20 and FP20Rha) to activate molecular circuits of innate immunity. These compounds are important drug hits in the development of vaccine adjuvants and tumor immunotherapeutics. The biological assays indicated that FP20Rha was more potent than FP20 in inducing cytokine production in cells and in stimulating IgG antibody production post-vaccination in mice. Accordingly, the overall significant IR spectral changes induced by the treatment with LPS and FP20Rha were similar, lipids and glycans signals being the most diagnostic, while the effect of the less potent molecule FP20 on cells resulted to be closer to control untreated cells. We propose here the use of FTIR spectroscopy supported by artificial intelligence (AI) to achieve a more holistic understanding of the cell response to new drug candidates while screening them in cells., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Antonino Natalello reports financial support was provided by University of Milano-Bicocca, Department of Biotechnology and Biosciences. Francesco Peri reports financial support was provided by University of Milano-Bicocca, Department of Biotechnology and Biosciences. Francesco Peri has patent #New synthetic agonists of TLR4 receptor licensed to Licensee. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF